clinical trial

[Ark Biopharmaceutical Co., Ltd.] Ark Biopharmaceutical Co., Ltd. announced the completion of patient enrollment and dosing of ziresovir for the treatment of respiratory syncytial virus infection in a Phase III registration clinical trial.

[Compass Therapeutics, Inc.] Compass Therapeutics, Inc. announced that the FDA has cleared its IND application for CTX-009, enabling the company to initiate a global Phase II clinical trial for CTX-009 in patients who have advanced Biliary Tract Cancers in the United States and South Korea.

[VYNE Therapeutics, Inc.] VYNE Therapeutics, Inc. announced that it has completed the Phase Ib portion of a Phase Ib/IIa clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis

[Current Opinion in infectious Diseases] Scientists review the most recent evidences concerning mycobacterial skin infections, limiting the period of literature research to 2020–2021.

[Ascletis Pharma, Inc.] Ascletis Pharma, Inc. announced the Investigational New Drug (IND) application approval by US FDA and initiation of global development of ASC22, a first-in-class, subcutaneously administered PD-L1 antibody for functional cure of chronic hepatitis B.

[Xilio Therapeutics, Inc.] Xilio Therapeutics, Inc. announced that the first patient has been dosed in the company’s Phase I/II clinical trial evaluating XTX202 for the treatment of solid tumors. XTX202 is a modified form of IL-2 that is designed to localize activity in the tumor microenvironment.